Evidence map›Paper›PMID 41387145›Full record

Trial reportJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2026

Correlates of FEV₁ deficit in pulmonary exacerbations of cystic fibrosis and associated clinical outcomes.

Oliver J McElvaney, Sonya L Heltshe, Don B Sanders, Natalie E West, Barbra Fogarty, Donald R VanDevanter, Patrick A Flume, Christopher H Goss, STOP2 Investigators

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02781610 (Standardized Treatment of Pulmonary Exacerbations II), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02781610 phase4completednot on this map

Standardized Treatment of Pulmonary Exacerbations II (STOP2)

TypeinterventionalSponsorChris GossRan2016 to 2020Enrolled982ConditionsPulmonary Cystic FibrosisArmsStandard of care IV antibiotic(s)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Oliver J McElvaneyDepartment of Medicine, University of Washington, Seattle WA, USA; Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle WA, USA.
Sonya L HeltsheDepartment of Medicine, University of Washington, Seattle WA, USA; Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle WA, USA; Department of Pediatrics, University of Washington, Seattle WA, USA.
Don B SandersDepartment of Pediatrics, Indiana University, Indianapolis IN, USA.
Natalie E WestDepartment of Medicine, Johns Hopkins University, Baltimore MD, USA.
Barbra FogartyCystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle WA, USA.
Donald R VanDevanterDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland OH, USA.
Patrick A FlumeDepartment of Pediatrics, Medical University of South Carolina, Charleston SC, USA; Department of Medicine, Medical University of South Carolina, Charleston SC, USA.
Christopher H GossDepartment of Medicine, University of Washington, Seattle WA, USA; Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle WA, USA; Department of Pediatrics, University of Washington, Seattle WA, USA. Electronic address: cgoss@medicine.washington.edu.
STOP2 Investigators

Funding

South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4M
NCATS NIH HHS UL1 TR001450NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

backgroundForced expiratory volume in 1 second (FEV

methodsWe performed a secondary analysis of STOP2 (NCT02781610), a multicenter randomized trial of intravenous antimicrobial treatment durations for CF PEx (n = 982). Factors associated with large FEV

resultsThe mean absolute decrease in percent-predicted FEV

conclusionsThese data may help identify those at risk for incomplete spirometric resolution following PEx and future PEx hazard. The presence of systemic inflammation serves as a marker of PEx severity.

Indexed as

Anti-Bacterial AgentsCystic FibrosisPseudomonas InfectionsAdultDisease ProgressionFemaleForced Expiratory VolumeHumansMalePseudomonas aeruginosaRespiratory Function TestsAnti-Bacterial AgentsClinical trialC-reactive proteinCystic fibrosisExacerbationFEV(1)InflammationSpirometry

Identifiers

PMID41387145
PMCPMC12829312

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.